Position of the Transparency Council – Yervoy (ipilimumab)
At its meeting on 22 August 2022 the Transparency Council adopted Position No. 79/2022 on the evaluation of drug: Yervoy (ipilimumab) under the drug programm: ,,Treatment of patients with advanced colorectal cancer (ICD-10: C18 – C20)”.